$GH

Saia John G. sold $1.3M of GH

Saia John G. (Chief Legal Officer) sold 10,000 shares of Guardant Health, Inc. (GH) at an average of $125.08 ($125.08–$126.08, $1.25M total) across 2 trades on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Saia John G.
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price range, total value) executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides incremental transparency on insider selling, but it is not a fundamental catalyst by itself.

03

What to watch

The filing does not state motivations; traders should compare with prior insider activity frequency and whether sales cluster around specific events (earnings, trial readouts).

Relevance 5/10Novelty 3/10Timing: filed 2026-05-28, transaction dated 2026-05-27

Background

The article is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health disclosed an insider Form 4 showing CFO John G. Saia sold about 10,000 shares in open-market trades under a 10b5-1 plan.

Expected impact

Likely minimal impact on the stock, unless investors extrapolate unusual selling beyond the plan.

Evidence & confidence

The filing specifies a Rule 10b5-1 pre-arranged plan and an open-market sale; the disclosed transaction is not tied to a new operational or regulatory event.

Market effects

No clear sector read-through; this is company-specific insider activity without new guidance or trial/regulatory updates.

None indicated.

None indicated.

Counterpoint

Insider sales can be interpreted as diversification rather than bearish information, especially when executed under a 10b5-1 plan.

Key entities

  • Guardant Health, Inc.

    Company whose insider transaction was disclosed on Form 4.

  • John G. Saia

    Chief Legal Officer who sold shares in open-market trades under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GRALMed

This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

$GHHighAI 9/10

Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role

Guardant Health (GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic for advanced HR-positive, HER2-negative breast cancer. This is the first FDA-approved liquid biopsy for longitudinal ctDNA testing in breast cancer. The approval was supported by clinical trial data showing early detection of ESR1 mutations. The company focuses on precision oncology, using blood and tissue tests to tailor cancer treatments. Investors should monitor the impact on future reve

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.